Rate and Risk Factors of Recurrent Immune Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer

Haitao Tao; Fangfang Li; Dongxiao Wu; Shiyu Ji; Qingyan Liu; Lijie Wang; Bo Liu; Francesco Facchinetti; Tracy L. Leong; Francesco Passiglia; Yi Hu


Transl Lung Cancer Res. 2022;11(3):381-392. 

In This Article


In conclusion, the results of this study showed that the recurrence of CIP in a real-world lung cancer patients' cohort receiving ICIs-therapies is not an uncommon event. Recurrence of CIP was more frequently reported in males, squamous histology or patients who received chest radiotherapy. Squamous NSCLC patients and a duration of prednisolone equivalent dose ≥15 mg/day more than 4 weeks have been associated with an decreased risk of CIP recurrence. Based on these findings a duration of prednisolone equivalent dose ≥15 mg/day of at least 4 weeks during the tapering process of corticosteroids may be warranted. Further studies including larger cohorts of patients are needed to verify this preliminary observation.